Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
about
P1343
Antimetastatic activity of a cyclooxygenase-2 inhibitorCyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancerAnthrax lethal toxin induces cell death-independent permeability in zebrafish vasculatureDevelopment of a rabbit pleural cancer model by using VX2 tumors.Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsVEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis.Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred miceRegulation of microvascular permeability by vascular endothelial growth factors.Castration-resistant prostate cancer: new science and therapeutic prospects.Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.Clinical implications for vascular endothelial growth factor in the lung: friend or foe?Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer.Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusionNuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.Malignant pleural effusion: tumor-host interactions unleashed.The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications.Switching off malignant pleural effusion formation-fantasy or future?Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma.Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
P2860
Q28169082-F285F09E-2B28-4EC0-91AE-56FAEED1BF59Q28193375-031B0A47-596A-429B-8E7A-26C2D6EE5FB4Q30481474-8CF73046-BE0D-4D8D-9679-BF492D1039B5Q33347764-3E2C9BF6-19F8-428D-B940-0669E2EEF121Q33391125-491411EE-191A-490D-8787-4A2CDC4B8AE6Q33424301-3FF90372-0B89-4A30-BD0B-028D42BF9D5CQ33901776-1518C27D-1ABE-42DD-BB01-310DB5B383BDQ34160907-5BFDB175-E194-4C5B-B9AA-5730553659FFQ34334465-84ED9295-B48D-4500-9609-E0DA4D77FE18Q34774011-285DA68D-0449-43D7-BA94-31B92F6D9E00Q35076264-6CD1E8B5-4433-4929-88BB-F8639A0AE13AQ35180077-88D4719D-4FA9-4781-9E27-1C0308B33C6DQ35689605-FD23B1A7-F086-4615-BE7C-B97136FB6CBCQ36392523-79287815-29A0-4872-87A8-96463DC2EA88Q36625050-4D41A4BC-A836-4092-A230-4CEE132157F2Q36643769-3BE01732-AB70-4FB2-AE32-CD44D04223C9Q36823307-29677215-FB15-4F9A-A7FE-9675709593DFQ36907325-8C06C82C-712D-41A9-A6BA-925427DFB3DDQ37101017-2380BC39-B6D8-46C4-9FC2-E23A550B7DFEQ38015001-27734102-7427-4C82-98F0-D67D633266C0Q38058513-9C8BE4CE-1590-41F1-BC4F-245473A49D12Q38543525-71031527-80C0-431B-82C9-4DFB17944606Q39358014-62D42FF8-684A-46B1-9928-A1B4B049C02AQ42220280-89571175-025A-4F0A-A395-DBEAE52521C2Q47163115-6F948D30-81F8-42F6-8CEA-3E8B1A817928Q47214627-10F31E2C-C2B0-48AA-B94A-2F5B992F4B6F
P2860
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Treatment for malignant pleura ...... rosine kinase phosphorylation.
@en
type
label
Treatment for malignant pleura ...... rosine kinase phosphorylation.
@en
prefLabel
Treatment for malignant pleura ...... rosine kinase phosphorylation.
@en
P2093
P921
P1476
Treatment for malignant pleura ...... yrosine kinase phosphorylation
@en
P2093
Killion JJ
Knighton B
Shinohara H
P304
P407
P4510
P577
2000-03-01T00:00:00Z